- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04220684
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the safety of adoptive NK cell therapy using membrane-bound interleukin-21 (mbIL21)-expanded, off-the-shelf, third-party donor-derived NK cells in patients with relapsed/refractory acute myeloid leukemia (AML).
SECONDARY OBJECTIVES:
I. Estimate the complete response (CR, CR with incomplete hematologic recovery [CRi] & morphologic leukemia-free state [MLFS]).
II. Estimate the median relapse free survival. III. Estimate the median time to neutrophil and platelet count recovery. IV. Estimate the median duration of remission. V. Estimate the incidence of infectious complications. VI. Estimate percentage of patients receiving this regimen who are rendered transplant-eligible.
CORRELATIVE OBJECTIVES:
I. Determine the persistence of ex-vivo expanded, off-the-shelf, third-party NK cells.
II. Characterize in vivo expansion of third-party NK cells and if it differs based on the conditioning regimen as defined by NK chimerism assay.
III. Determine the immunophenotype and function of expanded cells. IV. Chimerism analysis in patients who have had post-transplant relapses.
OUTLINE: This is a dose-escalation study of membrane-bound interleukin-21-expanded haploidentical natural killer cells.
INDUCTION: Patients receive fludarabine intravenously (IV) and cytarabine IV on days -6 to -2 in the absence of disease progression or unacceptable toxicity.
COHORT II: Patients who are >= 60 years old, unable/unwilling to tolerate intensive chemotherapy, or disease insensitive to cytarabine (tp53, TET2 mutations) receive fludarabine IV on days -5 to -2 and decitabine IV on days -6 to -2 in the absence of disease progression or unacceptable toxicity.
All patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells via infusion on days 0, 2, 4, 7, 9, and 11.
After completion of study treatment, patients are followed up to day 56.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: The Ohio State University Comprehensive Cancer Center
- Phone Number: 1-800-293-5066
- Email: OSUCCCClinicaltrials@osumc.edu
Study Contact Backup
- Name: Nicole Szuminski
- Phone Number: 614-688-9796
- Email: Nicole.Szuminski@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Sumithira Vasu, MBBS
- Phone Number: 614-293-8197
- Email: Sumithira.Vasu@osumc.edu
-
Principal Investigator:
- Sumithira Vasu, MBBS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patient Inclusion Criteria for Induction Phase
- Primary Relapsed AML including
- Relapsed AML after allogeneic stem cells
- Isolated CNS or extramedullary disease (Note: a response monitoring plan must be developed a priori for subjects with extramedullary disease)
- 1-3 prior lines of therapy which includes chemotherapy, hypomethylating agents, venetoclax or targeted therapy.
- Patient weight ≥ 42 kg
- Performance status: Karnofsky or Lansky Performance Scale (PS) greater or equal to 70, or, ECOG score 0-2.
- Renal function: Serum creatinine ≤ 2 mg/dl and/or creatinine clearance greater or equal than 40 cc/min.
- Pulmonary function: FEV1, FVC and DLCO ≥ 50% of expected, corrected for hemoglobin.
- Liver function: Total bilirubin ≤ 2 mg/dl or ≤ 2.5 x ULN for age (unless Gilbert's syndrome) and SGPT (ALT) ≤ 2.5 x ULN for age.
- Cardiac function: left ventricular ejection fraction ≥ 40%.
- CNS: Patients with seizure disorder are eligible if seizures well controlled.
- Negative serum test to rule out pregnancy within 2 weeks prior to enrollment in females of childbearing potential (non-childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized).
- Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator.
- Ability to understand and willingness to sign the written informed consent document.
- Negative serology for human immunodeficiency virus (HIV).
- Patients on hydrocortisone for adrenal insufficiency or on inhaled or topical steroids are eligible.
Maintenance Phase: Patients that complete induction therapy and who achieve a CR/CRi/PR within the designated follow-up period and who are ineligible, unable or unwilling to undergo HSCT; these patients will not receive fludarabine or cytarabine.
Exclusion Criteria for Induction Phase:
- Investigational therapies in the 3 weeks prior to beginning treatment on this protocol.
- Patients receiving any concurrent therapy including but not limited to chemotherapy, targeted therapy, radiation therapy, or immunotherapy for R/R AML.
- Any comorbidities that in the opinion of the investigator will preclude receiving fludarabine or cytarabine.
- Uncontrolled infection, defined as an infection which has not resolved spontaneously or does not show evidence of significant resolution after initiating appropriate therapy. Asymptomatic viremia such as CMV, HPV, BK virus, HCV, HBV etc. is NOT considered as an exclusion criteria.
- Uncontrolled arrhythmias or uncontrolled symptomatic cardiac disease.
- Active GVHD
- Prednisone dose is > 20 mg/day or >0.25mg/kg, whichever is higher will be excluded.
- Patients with donor-specific antibodies with MFI > 5000 will be ineligible
- Maintenance Phase: Patients must continue to meet exclusion criteria as defined in Section 4.4.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Conditioning Regimen
Fludarabine 30 mg/m2/day (day -6 to day -2) and Cytarabine 2g/ m2/day (days -6 to day -2)
|
Given IV
Other Names:
Given IV
Other Names:
|
Experimental: Induction
Six doses of third-party-donor mbIL-21 expanded (KDS-1001) cells given thrice weekly for two weeks.
Days may vary and KDS-1001 can be given from days 0 to 21
|
Given via infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) of membrane-bound interleukin-21-expanded haploidentical natural killer (NK) cells
Time Frame: Up to 63 days
|
The MTD will be defined as the highest safely tolerated dose where at most one patient in six experiences dose-limiting toxicity (DLT) during DLT observation period.
DLT is defined as any steroid refractory acute graft versus host disease.
|
Up to 63 days
|
Incidence of adverse events
Time Frame: Up to day 28
|
Toxicities will be assessed by type and grade using Common Terminology Criteria for Adverse Events version 5.0 and displayed in summary form by cohort and overall.
Toxicities will be summarized and reported regardless of attribution and also only those attributed to NK cells.
|
Up to day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response (CR)
Time Frame: Up to day 56
|
Response rate with a 95% confidence interval (CI) will be reported for all evaluable patients, assuming a binomial distribution.
Response rate will also be reported for those who received all 6 doses of NK cells.
|
Up to day 56
|
CR with incomplete hematologic recovery
Time Frame: Up to day 56
|
Response rate with a 95% CI will be reported for all evaluable patients, assuming a binomial distribution.
Response rate will also be reported for those who received all 6 doses of NK cells.
|
Up to day 56
|
Morphologic leukemia-free state
Time Frame: Up to day 56
|
Response rate with a 95% CI will be reported for all evaluable patients, assuming a binomial distribution.
Response rate will also be reported for those who received all 6 doses of NK cells.
|
Up to day 56
|
Median relapse free survival
Time Frame: Up to day 56
|
Will use descriptive statistics to summarize the demographic and clinical characteristics of the patients on this study.
|
Up to day 56
|
Median time to neutrophil and platelet count recovery
Time Frame: Up to day 56
|
Will use descriptive statistics to summarize the demographic and clinical characteristics of the patients on this study.
|
Up to day 56
|
Median duration of remission
Time Frame: Up to day 56
|
Will use descriptive statistics to summarize the demographic and clinical characteristics of the patients on this study.
|
Up to day 56
|
Incidence of infectious complications
Time Frame: Up to day 56
|
Will use descriptive statistics to summarize the demographic and clinical characteristics of the patients on this study.
|
Up to day 56
|
Percentage of patients receiving the regimen who are rendered transplant-eligible
Time Frame: Up to day 56
|
Will use descriptive statistics to summarize the demographic and clinical characteristics of the patients on this study.
|
Up to day 56
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of In-vivo expansion of NK cells
Time Frame: Up to day 56
|
Peripheral blood will be obtained before therapy, during the NK cell treatment period, and after NK cell treatment.
The studies may include flow cytometry analyses and sorting and molecular studies.
Donor NK-cell expansion will be defined as an absolute circulating donor-derived NK cell count that increases above the post-infusion level.
|
Up to day 56
|
Chimerism analysis to determine origin and number of circulating NK cells
Time Frame: Up to day 56
|
Chimerism may be determined by flow cytometry using haplotype-specific antibodies.
Chimerism may be determined by short tandem repeat polymorphisms.
When there is a sex-mismatch between the donor and the recipient, assays based on determining the frequency of sex-chromosomes may be used.
Testing may be altered by principal investigator or designee.
|
Up to day 56
|
Number of donor human leukocyte antigen (HLA) detection
Time Frame: Up to day 56
|
Donors with distinct HLA A or B antigens that can be detected by flow cytometry will be chosen.
This will enable tracking of infused cells.
|
Up to day 56
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sumithira Vasu, MBBS, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Fludarabine
- Cytarabine
Other Study ID Numbers
- OSU-18336
- NCI-2019-05150 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Acute Myeloid Leukemia
-
Sumithira VasuCompletedRecurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Minimal Residual DiseaseUnited States
-
National Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Donor | Hematopoietic Cell Transplant Recipient | HLA-A*0201 Positive Cells PresentUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on Fludarabine
-
National Institute of Arthritis and Musculoskeletal...CompletedPsoriasis | Arthritis, PsoriaticUnited States
-
Nantes University HospitalCyceronNot yet recruiting
-
Naoyuki G. Saito, M.D., Ph.D.WithdrawnAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Acute Lymphocytic LeukemiaUnited States
-
Emory UniversityCompletedSickle Cell Disease | Bone Marrow TransplantationUnited States
-
National Institute of Arthritis and Musculoskeletal...CompletedSystemic Lupus Erythematosus | Glomerulonephritis | Lupus NephritisUnited States
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceCompletedUntreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma PatientsFrance
-
University of Illinois at ChicagoCompletedAcute Myeloid Leukemia | Polycythemia Vera | Multiple Myeloma | Myelofibrosis | Acute Leukemia | Chronic Myelogenous Leukemia | Aplastic Anemia | Myeloproliferative Disorder | Hodgkin's Disease | Malignant Lymphoma | Lymphocytic LeukemiaUnited States
-
Zhujiang HospitalFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaboratorsUnknownLeukemia Relapse | Chronic Graft-versus-host-disease
-
Massachusetts General HospitalTerminatedMultiple Myeloma | Hodgkin Disease | Non Hodgkin's LymphomaUnited States
-
German CLL Study GroupCompletedAnemia | Chronic Lymphocytic LeukemiaGermany